- Home
- ADPT vs SEZL Comparison
ADPT vs SEZL Comparison
Compare ADPT & SEZL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADPT | SEZL |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ADPT | SEZL |
|---|---|---|
| Price | $12.44 | $65.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $17.78 | ★ $114.20 |
| AVG Volume (30 Days) | ★ 1.5M | 761.0K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 3.72 |
| Revenue | $276,976,000.00 | ★ $450,279,000.00 |
| Revenue This Year | $3.98 | $27.45 |
| Revenue Next Year | $22.72 | $26.94 |
| P/E Ratio | ★ N/A | $18.61 |
| Revenue Growth | 54.77 | ★ 66.08 |
| 52 Week Low | $6.68 | $25.00 |
| 52 Week High | $20.76 | $263.00 |
Technical Indicators
Market Signals| Indicator | ADPT | SEZL |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 46.01 |
| Support Level | $12.32 | $64.55 |
| Resistance Level | $13.45 | $75.37 |
| Average True Range (ATR) | 0.83 | 5.88 |
| MACD | -0.26 | -0.28 |
| Stochastic Oscillator | 10.61 | 33.63 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.